Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in adults with warm autoimmune hemolytic anemia
2023-505321-14-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of nipocalimab in warm autoimmune hemolytic anemia (wAIHA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Durable hemoglobin response, Primary endpoint timing rule and 1 more. Planned start Sep 2019; status: authorised.
02
Drugs
nipocalimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on 2023-505321-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505321-14-00.